Provided By GlobeNewswire
Last update: Jul 2, 2025
BERKELEY HEIGHTS, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-15 reverse stock split on its shares of common stock effective July 7, 2025, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the shares of common stock will continue on The Nasdaq Capital Market under the symbol “CYCC”. The new CUSIP number for the shares of common stock following the reverse stock split is 23254L876.
Read more at globenewswire.com16.04
-1.11 (-6.47%)
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (7/24/2025, 8:00:00 PM)
Premarket: 5.3 +0.46 (+9.5%)4.84
+0.19 (+4.09%)
Find more stocks in the Stock Screener